Sagimet Biosciences sets $107.5 million net share and warrant offering
Sagimet Biosciences agreed on September 30, 2026 to sell 8,750,010 shares of Series A common stock at $10.00 per share and pre-funded warrants for up to 2,750,010 shares, with net proceeds expected to be $107.5 million. The company plans to use the proceeds with its existing cash to fund a Phase 3 trial of denifanstat in acne, pre-launch activities, and other clinical and corporate needs, and the offering is expected to close on October 1, 2026.
Key points
- 8,750,010 common shares offered at $10.00 per share, plus pre-funded warrants for up to 2,750,010 shares
- Expected net proceeds of $107.5 million after underwriting discounts and commissions
- Offering expected to close October 1, 2026, subject to customary closing conditions
- Underwriters include Leerink Partners LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC as representatives
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.